 [
    {
        "id": 6400,
        "drug_name": "VENCLEXTA (venetoclax) - (VIALE-A)",
        "clinical_trial_id": "NCT02993523",
        "has_trial_insight_page": 0,
        "indication": "Acute Myeloid Leukemia (AML)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-10-16",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/venclexta-venetoclax-receives-fda-full-approval-for-acute-myeloid-leukemia-aml-301154267.html",
        "note": "FDA approval announced October 16, 2020.",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2364,
        "drug_name": "EYSUVIS (KPI\u2011121) 0.25%",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Dry eye disease",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-10-27",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20201027005351\/en\/",
        "note": "",
        "company_entity_id": 447,
        "company_ticker": "KALA",
        "company_name": "KALA BIO Inc.",
        "company_price": "7.5700",
        "company_change": -0.25,
        "company_percent_change": -3.2,
        "company_optionable": 0,
        "company_number_of_shares": 2693116,
        "price_change_sparkline": [
            [
                6.95,
                1706677200
            ],
            [
                6.88,
                1706763600
            ],
            [
                6.96,
                1706850000
            ],
            [
                6.97,
                1707109200
            ],
            [
                7.0099,
                1707195600
            ],
            [
                6.98,
                1707282000
            ],
            [
                6.94,
                1707368400
            ],
            [
                7.37,
                1707454800
            ],
            [
                7.18,
                1707714000
            ],
            [
                6.99,
                1707800400
            ],
            [
                6.87,
                1707886800
            ],
            [
                7.18,
                1707973200
            ],
            [
                7.09,
                1708059600
            ],
            [
                7.17,
                1708405200
            ],
            [
                7.14,
                1708491600
            ],
            [
                7.9999,
                1708578000
            ],
            [
                7.06,
                1708664400
            ],
            [
                7.2336,
                1708923600
            ],
            [
                7.15,
                1709010000
            ],
            [
                7.185,
                1709096400
            ],
            [
                7.18,
                1709182800
            ],
            [
                7.33,
                1709269200
            ],
            [
                7.66,
                1709528400
            ],
            [
                7.475,
                1709614800
            ],
            [
                7.49,
                1709701200
            ],
            [
                7.33,
                1709787600
            ],
            [
                7.5,
                1709874000
            ],
            [
                7.82,
                1710129600
            ],
            [
                7.57,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5235,
        "drug_name": "BRILINTA (ticagrelor) - (THALES)",
        "clinical_trial_id": "NCT03354429",
        "has_trial_insight_page": 0,
        "indication": "Acute ischaemic stroke",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-11-06",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20201106005212\/en\/",
        "note": "FDA approval announced November 6, 2020.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6685,
        "drug_name": "BamlanivimabLY-CoV555",
        "clinical_trial_id": "NCT04427501",
        "has_trial_insight_page": 0,
        "indication": "COVID-19 Antibody",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-11-09",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/lillys-neutralizing-antibody-bamlanivimab-ly-cov555-receives-fda-emergency-use-authorization-for-the-treatment-of-recently-diagnosed-covid-19-301169147.html",
        "note": "Emergency Use Authorization (EUA) announced November 9, 2020. ",
        "company_entity_id": 863,
        "company_ticker": "ABCL",
        "company_name": "AbCellera Biologics Inc.",
        "company_price": "4.8800",
        "company_change": -0.07999999999999996,
        "company_percent_change": -1.6099999999999999,
        "company_optionable": 1,
        "company_number_of_shares": 289355867,
        "price_change_sparkline": [
            [
                5.11,
                1706677200
            ],
            [
                5.2,
                1706763600
            ],
            [
                5.01,
                1706850000
            ],
            [
                4.95,
                1707109200
            ],
            [
                5.18,
                1707195600
            ],
            [
                4.91,
                1707282000
            ],
            [
                5.02,
                1707368400
            ],
            [
                5.11,
                1707454800
            ],
            [
                5.46,
                1707714000
            ],
            [
                5.11,
                1707800400
            ],
            [
                5.22,
                1707886800
            ],
            [
                5.28,
                1707973200
            ],
            [
                5.34,
                1708059600
            ],
            [
                5.31,
                1708405200
            ],
            [
                4.81,
                1708491600
            ],
            [
                4.85,
                1708578000
            ],
            [
                4.87,
                1708664400
            ],
            [
                4.95,
                1708923600
            ],
            [
                5.12,
                1709010000
            ],
            [
                5.08,
                1709096400
            ],
            [
                5.05,
                1709182800
            ],
            [
                5.05,
                1709269200
            ],
            [
                5,
                1709528400
            ],
            [
                4.81,
                1709614800
            ],
            [
                4.87,
                1709701200
            ],
            [
                4.91,
                1709787600
            ],
            [
                4.77,
                1709874000
            ],
            [
                4.96,
                1710129600
            ],
            [
                4.88,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6685,
        "drug_name": "BamlanivimabLY-CoV555",
        "clinical_trial_id": "NCT04427501",
        "has_trial_insight_page": 0,
        "indication": "COVID-19 Antibody",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-11-09",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/lillys-neutralizing-antibody-bamlanivimab-ly-cov555-receives-fda-emergency-use-authorization-for-the-treatment-of-recently-diagnosed-covid-19-301169147.html",
        "note": "Emergency Use Authorization (EUA) announced November 9, 2020. ",
        "company_entity_id": 382,
        "company_ticker": "LLY",
        "company_name": "Eli Lilly and Company",
        "company_price": "754.9500",
        "company_change": 20.58,
        "company_percent_change": 2.8,
        "company_optionable": 1,
        "company_number_of_shares": 950164452,
        "price_change_sparkline": [
            [
                644.503643637706,
                1706677200
            ],
            [
                659.298247188938,
                1706763600
            ],
            [
                666.505874560051,
                1706850000
            ],
            [
                704.989812947364,
                1707109200
            ],
            [
                703.821817930162,
                1707195600
            ],
            [
                724.13694493877,
                1707282000
            ],
            [
                734.41929423551,
                1707368400
            ],
            [
                738.891617036422,
                1707454800
            ],
            [
                735.996586651903,
                1707714000
            ],
            [
                741.696801650387,
                1707800400
            ],
            [
                757.31,
                1707886800
            ],
            [
                757.78,
                1707973200
            ],
            [
                782.06,
                1708059600
            ],
            [
                755.66,
                1708405200
            ],
            [
                745.91,
                1708491600
            ],
            [
                769.64,
                1708578000
            ],
            [
                769.54,
                1708664400
            ],
            [
                771.92,
                1708923600
            ],
            [
                765,
                1709010000
            ],
            [
                757.64,
                1709096400
            ],
            [
                753.68,
                1709182800
            ],
            [
                782.12,
                1709269200
            ],
            [
                792.28,
                1709528400
            ],
            [
                777.59,
                1709614800
            ],
            [
                779.77,
                1709701200
            ],
            [
                780.16,
                1709787600
            ],
            [
                762.14,
                1709874000
            ],
            [
                734.37,
                1710129600
            ],
            [
                754.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5105,
        "drug_name": "ZOKINVY (Lonafarnib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Hutchinson-Gilford Progeria Syndrome (HGPS)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-11-20",
        "link": "https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-hutchinson-gilford-progeria-syndrome-and-some-progeroid-laminopathies",
        "note": "FDA approval announced November 20, 2020.",
        "company_entity_id": 129,
        "company_ticker": "EIGR",
        "company_name": "Eiger BioPharmaceuticals Inc.",
        "company_price": "5.9000",
        "company_change": -0.86,
        "company_percent_change": -12.72,
        "company_optionable": 1,
        "company_number_of_shares": 1479489,
        "price_change_sparkline": [
            [
                6.89,
                1706677200
            ],
            [
                6.55,
                1706763600
            ],
            [
                6.51,
                1706850000
            ],
            [
                6.52,
                1707109200
            ],
            [
                6.39,
                1707195600
            ],
            [
                6.4,
                1707282000
            ],
            [
                5.96,
                1707368400
            ],
            [
                5.76,
                1707454800
            ],
            [
                5.81,
                1707714000
            ],
            [
                5.8199,
                1707800400
            ],
            [
                5.8,
                1707886800
            ],
            [
                5.68,
                1707973200
            ],
            [
                5.73,
                1708059600
            ],
            [
                5.7399,
                1708405200
            ],
            [
                5.8,
                1708491600
            ],
            [
                5.8,
                1708578000
            ],
            [
                5.41,
                1708664400
            ],
            [
                5.7999,
                1708923600
            ],
            [
                5.81,
                1709010000
            ],
            [
                5.7906,
                1709096400
            ],
            [
                5.6,
                1709182800
            ],
            [
                7,
                1709269200
            ],
            [
                6.195,
                1709528400
            ],
            [
                6.95,
                1709614800
            ],
            [
                6.799,
                1709701200
            ],
            [
                7.18,
                1709787600
            ],
            [
                6.9144,
                1709874000
            ],
            [
                6.76,
                1710129600
            ],
            [
                5.9,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6526,
        "drug_name": "XOFLUZA (baloxavir marboxil)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Acute uncomplicated influenza (12 years and older)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-11-23",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20201123006213\/en\/",
        "note": "FDA approval announced November 23, 2020.",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7246,
        "drug_name": "TIVICAY (dolutegravir)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Pediatric Formulation of Dolutegravir (DTG)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-11-23",
        "link": "https:\/\/www.benzinga.com\/pressreleases\/20\/11\/n18498387\/viatris-inc-announces-fda-tentative-approval-of-a-pediatric-formulation-of-dolutegravir-dtg-under-",
        "note": "FDA tentative approval announced November 23, 2020.",
        "company_entity_id": 851,
        "company_ticker": "VTRS",
        "company_name": "Viatris Inc.",
        "company_price": "12.0600",
        "company_change": 0.09,
        "company_percent_change": 0.75,
        "company_optionable": 1,
        "company_number_of_shares": 1187569149,
        "price_change_sparkline": [
            [
                11.6559127625202,
                1706677200
            ],
            [
                11.754943457189,
                1706763600
            ],
            [
                11.7351373182553,
                1706850000
            ],
            [
                11.4677544426494,
                1707109200
            ],
            [
                11.7747495961228,
                1707195600
            ],
            [
                11.6262035541195,
                1707282000
            ],
            [
                11.4479483037157,
                1707368400
            ],
            [
                11.5667851373183,
                1707454800
            ],
            [
                11.8341680129241,
                1707714000
            ],
            [
                11.8539741518578,
                1707800400
            ],
            [
                11.9530048465267,
                1707886800
            ],
            [
                12.6957350565428,
                1707973200
            ],
            [
                12.933408723748,
                1708059600
            ],
            [
                13.1116639741519,
                1708405200
            ],
            [
                13.1314701130856,
                1708491600
            ],
            [
                13.2305008077544,
                1708578000
            ],
            [
                13.3988529886914,
                1708664400
            ],
            [
                13.2998222940226,
                1708923600
            ],
            [
                13.101760904685,
                1709010000
            ],
            [
                12.1708723747981,
                1709096400
            ],
            [
                12.2500969305331,
                1709182800
            ],
            [
                12.4679644588045,
                1709269200
            ],
            [
                12.2401938610662,
                1709528400
            ],
            [
                12.1609693053312,
                1709614800
            ],
            [
                12.0817447495961,
                1709701200
            ],
            [
                12.2104846526656,
                1709787600
            ],
            [
                12.26,
                1709874000
            ],
            [
                11.97,
                1710129600
            ],
            [
                12.06,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3908,
        "drug_name": "OXLUMO (lumasiran)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Primary Hyperoxaluria Type 1 (PH1)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-11-24",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20201124005407\/en\/",
        "note": "FDA approval announced November 24, 2020.",
        "company_entity_id": 32,
        "company_ticker": "ALNY",
        "company_name": "Alnylam Pharmaceuticals Inc.",
        "company_price": "146.6500",
        "company_change": -2.45,
        "company_percent_change": -1.6400000000000001,
        "company_optionable": 1,
        "company_number_of_shares": 125945793,
        "price_change_sparkline": [
            [
                172.91,
                1706677200
            ],
            [
                174.92,
                1706763600
            ],
            [
                173.06,
                1706850000
            ],
            [
                170.7,
                1707109200
            ],
            [
                172.18,
                1707195600
            ],
            [
                168.6,
                1707282000
            ],
            [
                169.5,
                1707368400
            ],
            [
                170.03,
                1707454800
            ],
            [
                169.34,
                1707714000
            ],
            [
                162,
                1707800400
            ],
            [
                164.15,
                1707886800
            ],
            [
                147.43,
                1707973200
            ],
            [
                147,
                1708059600
            ],
            [
                149.69,
                1708405200
            ],
            [
                154.74,
                1708491600
            ],
            [
                162.81,
                1708578000
            ],
            [
                157.65,
                1708664400
            ],
            [
                158.66,
                1708923600
            ],
            [
                159,
                1709010000
            ],
            [
                155.23,
                1709096400
            ],
            [
                151.09,
                1709182800
            ],
            [
                152.61,
                1709269200
            ],
            [
                150.04,
                1709528400
            ],
            [
                149.68,
                1709614800
            ],
            [
                149.66,
                1709701200
            ],
            [
                149.86,
                1709787600
            ],
            [
                149.82,
                1709874000
            ],
            [
                149.1,
                1710129600
            ],
            [
                146.65,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5793,
        "drug_name": "DANYELZA (Naxitamab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Neuroblastoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-11-25",
        "link": "https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761171",
        "note": "FDA approval announced November 25, 2020.",
        "company_entity_id": 658,
        "company_ticker": "YMAB",
        "company_name": "Y-mAbs Therapeutics Inc.",
        "company_price": "16.0900",
        "company_change": -0.4,
        "company_percent_change": -2.43,
        "company_optionable": 1,
        "company_number_of_shares": 43777105,
        "price_change_sparkline": [
            [
                12.79,
                1706677200
            ],
            [
                13.39,
                1706763600
            ],
            [
                14,
                1706850000
            ],
            [
                13.67,
                1707109200
            ],
            [
                13.59,
                1707195600
            ],
            [
                13.05,
                1707282000
            ],
            [
                12.97,
                1707368400
            ],
            [
                13.11,
                1707454800
            ],
            [
                14.36,
                1707714000
            ],
            [
                14.88,
                1707800400
            ],
            [
                15.2,
                1707886800
            ],
            [
                16,
                1707973200
            ],
            [
                16.29,
                1708059600
            ],
            [
                16.55,
                1708405200
            ],
            [
                16.47,
                1708491600
            ],
            [
                17.01,
                1708578000
            ],
            [
                16.51,
                1708664400
            ],
            [
                16.5,
                1708923600
            ],
            [
                16.5,
                1709010000
            ],
            [
                16.33,
                1709096400
            ],
            [
                16.7,
                1709182800
            ],
            [
                18.69,
                1709269200
            ],
            [
                17.33,
                1709528400
            ],
            [
                16.64,
                1709614800
            ],
            [
                17.99,
                1709701200
            ],
            [
                17.64,
                1709787600
            ],
            [
                17.62,
                1709874000
            ],
            [
                16.49,
                1710129600
            ],
            [
                16.09,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2343,
        "drug_name": "Setmelanotide",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "POMC deficiency obesity \/ Leptin Receptor Deficiency Obesity",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-11-27",
        "link": "https:\/\/ir.rhythmtx.com\/news-releases\/news-release-details\/rhythm-pharmaceuticals-announces-fda-approval-imcivreetm",
        "note": "FDA approval announced November 27, 2020.",
        "company_entity_id": 455,
        "company_ticker": "RYTM",
        "company_name": "Rhythm Pharmaceuticals Inc.",
        "company_price": "40.1800",
        "company_change": -0.32999999999999996,
        "company_percent_change": -0.81,
        "company_optionable": 1,
        "company_number_of_shares": 60140495,
        "price_change_sparkline": [
            [
                44.11,
                1706677200
            ],
            [
                46.33,
                1706763600
            ],
            [
                44.88,
                1706850000
            ],
            [
                45.99,
                1707109200
            ],
            [
                47.64,
                1707195600
            ],
            [
                47.79,
                1707282000
            ],
            [
                47.55,
                1707368400
            ],
            [
                51.18,
                1707454800
            ],
            [
                52.44,
                1707714000
            ],
            [
                48.9,
                1707800400
            ],
            [
                50.05,
                1707886800
            ],
            [
                50.47,
                1707973200
            ],
            [
                49.23,
                1708059600
            ],
            [
                49.11,
                1708405200
            ],
            [
                48.81,
                1708491600
            ],
            [
                44.06,
                1708578000
            ],
            [
                45.16,
                1708664400
            ],
            [
                46.15,
                1708923600
            ],
            [
                46.03,
                1709010000
            ],
            [
                44.38,
                1709096400
            ],
            [
                43.42,
                1709182800
            ],
            [
                43.71,
                1709269200
            ],
            [
                42.12,
                1709528400
            ],
            [
                41.24,
                1709614800
            ],
            [
                41.1,
                1709701200
            ],
            [
                41.67,
                1709787600
            ],
            [
                41.94,
                1709874000
            ],
            [
                40.51,
                1710129600
            ],
            [
                40.18,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5847,
        "drug_name": "XOLAIR (omalizumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Chronic rhinosinusitis with nasal polyps (CRSwNP)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-12-01",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20201201005918\/en\/",
        "note": "FDA approval announced December 1, 2020.",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3975,
        "drug_name": "HETLIOZ (tasimelteon)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Smith-Magenis Syndrome",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-12-01",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/fda-approves-hetlioz-tasimelteon-for-the-treatment-of-nighttime-sleep-disturbances-in-smith-magenis-syndrome-301183162.html",
        "note": "FDA approval announced December 1, 2020.",
        "company_entity_id": 305,
        "company_ticker": "VNDA",
        "company_name": "Vanda Pharmaceuticals Inc.",
        "company_price": "3.8800",
        "company_change": -0.13,
        "company_percent_change": -3.12,
        "company_optionable": 1,
        "company_number_of_shares": 57537499,
        "price_change_sparkline": [
            [
                3.6,
                1706677200
            ],
            [
                3.73,
                1706763600
            ],
            [
                3.63,
                1706850000
            ],
            [
                3.47,
                1707109200
            ],
            [
                3.73,
                1707195600
            ],
            [
                3.64,
                1707282000
            ],
            [
                4.07,
                1707368400
            ],
            [
                4.16,
                1707454800
            ],
            [
                4.33,
                1707714000
            ],
            [
                4.06,
                1707800400
            ],
            [
                4.25,
                1707886800
            ],
            [
                4.37,
                1707973200
            ],
            [
                4.38,
                1708059600
            ],
            [
                4.35,
                1708405200
            ],
            [
                4.34,
                1708491600
            ],
            [
                4.33,
                1708578000
            ],
            [
                4.45,
                1708664400
            ],
            [
                4.56,
                1708923600
            ],
            [
                4.59,
                1709010000
            ],
            [
                4.47,
                1709096400
            ],
            [
                4.47,
                1709182800
            ],
            [
                4.61,
                1709269200
            ],
            [
                4.27,
                1709528400
            ],
            [
                4.14,
                1709614800
            ],
            [
                3.91,
                1709701200
            ],
            [
                3.82,
                1709787600
            ],
            [
                3.87,
                1709874000
            ],
            [
                4.01,
                1710129600
            ],
            [
                3.88,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6293,
        "drug_name": "GAVRETO (Pralsetinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "RET-mutant medullary thyroid cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-12-01",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/blueprint-medicines-announces-fda-approval-of-gavreto-pralsetinib-for-the-treatment-of-patients-with-advanced-or-metastatic-ret-mutant-and-ret-fusion-positive-thyroid-cancer-301183017.html",
        "note": "FDA approval announced December 1, 2020.",
        "company_entity_id": 439,
        "company_ticker": "BPMC",
        "company_name": "Blueprint Medicines Corporation",
        "company_price": "89.7000",
        "company_change": 0.23,
        "company_percent_change": 0.26,
        "company_optionable": 1,
        "company_number_of_shares": 61232297,
        "price_change_sparkline": [
            [
                79.53,
                1706677200
            ],
            [
                79.88,
                1706763600
            ],
            [
                79.58,
                1706850000
            ],
            [
                76.66,
                1707109200
            ],
            [
                77.17,
                1707195600
            ],
            [
                74.2,
                1707282000
            ],
            [
                74.16,
                1707368400
            ],
            [
                76.54,
                1707454800
            ],
            [
                77.54,
                1707714000
            ],
            [
                73.17,
                1707800400
            ],
            [
                76.8,
                1707886800
            ],
            [
                87.57,
                1707973200
            ],
            [
                90.26,
                1708059600
            ],
            [
                91.25,
                1708405200
            ],
            [
                87.26,
                1708491600
            ],
            [
                86,
                1708578000
            ],
            [
                89.49,
                1708664400
            ],
            [
                95.05,
                1708923600
            ],
            [
                99.79,
                1709010000
            ],
            [
                95.45,
                1709096400
            ],
            [
                93.52,
                1709182800
            ],
            [
                95.12,
                1709269200
            ],
            [
                90.8,
                1709528400
            ],
            [
                89.67,
                1709614800
            ],
            [
                90.38,
                1709701200
            ],
            [
                92.04,
                1709787600
            ],
            [
                92.3,
                1709874000
            ],
            [
                89.47,
                1710129600
            ],
            [
                89.7,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3395,
        "drug_name": "ORLADEYO (Berotralstat)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Reduce or eliminate attacks in HAE patients ",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-12-03",
        "link": "https:\/\/ir.biocryst.com\/news-releases\/news-release-details\/biocryst-announces-fda-approval-orladeyotm-berotralstat-first",
        "note": "FDA approval announced December 3, 2020",
        "company_entity_id": 63,
        "company_ticker": "BCRX",
        "company_name": "BioCryst Pharmaceuticals Inc.",
        "company_price": "5.1400",
        "company_change": -0.18000000000000005,
        "company_percent_change": -3.38,
        "company_optionable": 1,
        "company_number_of_shares": 206149929,
        "price_change_sparkline": [
            [
                5.3,
                1706677200
            ],
            [
                5.28,
                1706763600
            ],
            [
                5.08,
                1706850000
            ],
            [
                5.14,
                1707109200
            ],
            [
                5.51,
                1707195600
            ],
            [
                5.3,
                1707282000
            ],
            [
                5.32,
                1707368400
            ],
            [
                5.85,
                1707454800
            ],
            [
                5.95,
                1707714000
            ],
            [
                5.32,
                1707800400
            ],
            [
                5.57,
                1707886800
            ],
            [
                5.64,
                1707973200
            ],
            [
                5.92,
                1708059600
            ],
            [
                5.82,
                1708405200
            ],
            [
                5.65,
                1708491600
            ],
            [
                5.82,
                1708578000
            ],
            [
                5.71,
                1708664400
            ],
            [
                5.79,
                1708923600
            ],
            [
                5.87,
                1709010000
            ],
            [
                5.71,
                1709096400
            ],
            [
                5.63,
                1709182800
            ],
            [
                5.62,
                1709269200
            ],
            [
                5.51,
                1709528400
            ],
            [
                5.41,
                1709614800
            ],
            [
                5.21,
                1709701200
            ],
            [
                5.18,
                1709787600
            ],
            [
                5.43,
                1709874000
            ],
            [
                5.32,
                1710129600
            ],
            [
                5.14,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3625,
        "drug_name": "TLANDO (LPCN 1021)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Men with low testosterone (Low T)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-12-08",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/lipocine-announces-tentative-approval-of-tlando-301188975.html",
        "note": "FDA tentative approval announced December 8, 2020.",
        "company_entity_id": 189,
        "company_ticker": "LPCN",
        "company_name": "Lipocine Inc.",
        "company_price": "3.9600",
        "company_change": 0.35,
        "company_percent_change": 9.7,
        "company_optionable": 0,
        "company_number_of_shares": 5315830,
        "price_change_sparkline": [
            [
                3.9,
                1706677200
            ],
            [
                3.98,
                1706763600
            ],
            [
                3.94,
                1706850000
            ],
            [
                3.93,
                1707109200
            ],
            [
                4.09,
                1707195600
            ],
            [
                3.93,
                1707282000
            ],
            [
                4.01,
                1707368400
            ],
            [
                3.97,
                1707454800
            ],
            [
                4,
                1707714000
            ],
            [
                3.98,
                1707800400
            ],
            [
                4.09,
                1707886800
            ],
            [
                4.01,
                1707973200
            ],
            [
                4.01,
                1708059600
            ],
            [
                4,
                1708405200
            ],
            [
                3.95,
                1708491600
            ],
            [
                3.9,
                1708578000
            ],
            [
                3.81,
                1708664400
            ],
            [
                3.86,
                1708923600
            ],
            [
                3.86,
                1709010000
            ],
            [
                3.88,
                1709096400
            ],
            [
                3.81,
                1709182800
            ],
            [
                3.83,
                1709269200
            ],
            [
                3.65,
                1709528400
            ],
            [
                3.64,
                1709614800
            ],
            [
                3.58,
                1709701200
            ],
            [
                3.63,
                1709787600
            ],
            [
                3.61,
                1709874000
            ],
            [
                3.61,
                1710129600
            ],
            [
                3.96,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2475,
        "drug_name": "Tirbanibulin ointment",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Actinic keratosis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-12-15",
        "link": "https:\/\/www.benzinga.com\/pressreleases\/20\/12\/n18790878\/almirall-announces-fda-approval-of-klisyri-tirbanibulin-a-new-innovative-topical-treatment-for-act",
        "note": "FDA approval announced December 15, 2020.",
        "company_entity_id": 2254,
        "company_ticker": "ATNXQ",
        "company_name": "Athenex Inc.",
        "company_price": "0.0152",
        "company_change": 0,
        "company_percent_change": 0,
        "company_optionable": 0,
        "company_number_of_shares": 433160,
        "statuses": []
    },
    {
        "id": 6275,
        "drug_name": "BENLYSTA  (belimumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Lupus Nephritis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-12-17",
        "link": "https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/fda-approves-gsk-s-benlysta-as-the-first-medicine-for-adult-patients-with-active-lupus-nephritis-in-the-us\/",
        "note": "FDA approval announced December 17, 2020.",
        "company_entity_id": 379,
        "company_ticker": "GSK",
        "company_name": "GSK plc American Depositary Shares (Each representing two)",
        "company_price": "43.2700",
        "company_change": 0.35,
        "company_percent_change": 0.82,
        "company_optionable": 1,
        "company_number_of_shares": 2058516719,
        "price_change_sparkline": [
            [
                39.0637603938206,
                1706677200
            ],
            [
                40.2424083367376,
                1706763600
            ],
            [
                40.3315497777986,
                1706850000
            ],
            [
                41.1734411655964,
                1707109200
            ],
            [
                41.3517240477183,
                1707195600
            ],
            [
                41.6191483709012,
                1707282000
            ],
            [
                41.4210562796546,
                1707368400
            ],
            [
                41.5101977207156,
                1707454800
            ],
            [
                40.67821093748,
                1707714000
            ],
            [
                40.9951582834745,
                1707800400
            ],
            [
                41.40124707053,
                1707886800
            ],
            [
                41.371533256843,
                1707973200
            ],
            [
                41.5399115344025,
                1708059600
            ],
            [
                41.6191483709012,
                1708405200
            ],
            [
                41.5399115344025,
                1708491600
            ],
            [
                42.16,
                1708578000
            ],
            [
                42.22,
                1708664400
            ],
            [
                42.34,
                1708923600
            ],
            [
                42.38,
                1709010000
            ],
            [
                42.34,
                1709096400
            ],
            [
                41.9,
                1709182800
            ],
            [
                42.03,
                1709269200
            ],
            [
                42.44,
                1709528400
            ],
            [
                42.6,
                1709614800
            ],
            [
                42.62,
                1709701200
            ],
            [
                43.58,
                1709787600
            ],
            [
                43.14,
                1709874000
            ],
            [
                42.92,
                1710129600
            ],
            [
                43.27,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2995,
        "drug_name": "RIABNI (rituximab-arrx)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "RITUXAN biosimilar - non-Hodgkin lymphoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-12-17",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/fda-approves-amgens-riabni-rituximab-arrx-a-biosimilar-to-rituxan-rituximab-301195492.html",
        "note": "FDA approval announced December 17, 2020.",
        "company_entity_id": 372,
        "company_ticker": "AMGN",
        "company_name": "Amgen Inc.",
        "company_price": "276.5400",
        "company_change": 1.18,
        "company_percent_change": 0.43,
        "company_optionable": 1,
        "company_number_of_shares": 535918901,
        "price_change_sparkline": [
            [
                311.832823699025,
                1706677200
            ],
            [
                322.053272003295,
                1706763600
            ],
            [
                320.693853151174,
                1706850000
            ],
            [
                319.483275779212,
                1707109200
            ],
            [
                313.62884422628,
                1707195600
            ],
            [
                293.584858231498,
                1707282000
            ],
            [
                292.572736166415,
                1707368400
            ],
            [
                288.871544693121,
                1707454800
            ],
            [
                292.155980021969,
                1707714000
            ],
            [
                288.236487711108,
                1707800400
            ],
            [
                287.829654332006,
                1707886800
            ],
            [
                289.07,
                1707973200
            ],
            [
                283.7,
                1708059600
            ],
            [
                283.51,
                1708405200
            ],
            [
                283.46,
                1708491600
            ],
            [
                285.18,
                1708578000
            ],
            [
                289.18,
                1708664400
            ],
            [
                286.37,
                1708923600
            ],
            [
                278.49,
                1709010000
            ],
            [
                277.46,
                1709096400
            ],
            [
                273.83,
                1709182800
            ],
            [
                280.33,
                1709269200
            ],
            [
                279.39,
                1709528400
            ],
            [
                276.65,
                1709614800
            ],
            [
                276.59,
                1709701200
            ],
            [
                272.86,
                1709787600
            ],
            [
                273.75,
                1709874000
            ],
            [
                275.36,
                1710129600
            ],
            [
                276.54,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6654,
        "drug_name": "ICLUSIG (ponatinib)",
        "clinical_trial_id": "NCT02467270",
        "has_trial_insight_page": 0,
        "indication": "Chronic Myeloid Leukemia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-12-18",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20201218005716\/en\/",
        "note": "FDA approval announced December 18, 2020.",
        "company_entity_id": 751,
        "company_ticker": "TAK",
        "company_name": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1\/2 of a share of)",
        "company_price": "14.3700",
        "company_change": -0.19999999999999996,
        "company_percent_change": -1.37,
        "company_optionable": 1,
        "company_number_of_shares": 3137776702,
        "price_change_sparkline": [
            [
                14.6,
                1706677200
            ],
            [
                14.38,
                1706763600
            ],
            [
                14.28,
                1706850000
            ],
            [
                13.92,
                1707109200
            ],
            [
                14.16,
                1707195600
            ],
            [
                14.18,
                1707282000
            ],
            [
                14,
                1707368400
            ],
            [
                14.24,
                1707454800
            ],
            [
                14.31,
                1707714000
            ],
            [
                14.34,
                1707800400
            ],
            [
                14.54,
                1707886800
            ],
            [
                14.42,
                1707973200
            ],
            [
                14.62,
                1708059600
            ],
            [
                14.82,
                1708405200
            ],
            [
                14.74,
                1708491600
            ],
            [
                14.64,
                1708578000
            ],
            [
                14.62,
                1708664400
            ],
            [
                14.81,
                1708923600
            ],
            [
                14.84,
                1709010000
            ],
            [
                14.65,
                1709096400
            ],
            [
                14.59,
                1709182800
            ],
            [
                14.56,
                1709269200
            ],
            [
                14.48,
                1709528400
            ],
            [
                14.4,
                1709614800
            ],
            [
                14.69,
                1709701200
            ],
            [
                14.86,
                1709787600
            ],
            [
                14.77,
                1709874000
            ],
            [
                14.57,
                1710129600
            ],
            [
                14.37,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3613,
        "drug_name": "XPOVIO (selinexor)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Multiple myeloma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-12-18",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/karyopharm-announces-fda-approval-of-xpovio-selinexor-as-a-treatment-for-patients-with-multiple-myeloma-after-at-least-one-prior-therapy-301196120.html",
        "note": "FDA approval announced December 18, 2020.",
        "company_entity_id": 183,
        "company_ticker": "KPTI",
        "company_name": "Karyopharm Therapeutics Inc.",
        "company_price": "1.4500",
        "company_change": -0.030000000000000027,
        "company_percent_change": -2.0300000000000002,
        "company_optionable": 1,
        "company_number_of_shares": 115067083,
        "price_change_sparkline": [
            [
                0.7505,
                1706677200
            ],
            [
                0.9003,
                1706763600
            ],
            [
                1.04,
                1706850000
            ],
            [
                1.35,
                1707109200
            ],
            [
                1.66,
                1707195600
            ],
            [
                1.525,
                1707282000
            ],
            [
                1.51,
                1707368400
            ],
            [
                1.34,
                1707454800
            ],
            [
                1.3,
                1707714000
            ],
            [
                1.285,
                1707800400
            ],
            [
                1.36,
                1707886800
            ],
            [
                1.3,
                1707973200
            ],
            [
                1.27,
                1708059600
            ],
            [
                1.21,
                1708405200
            ],
            [
                1.21,
                1708491600
            ],
            [
                1.13,
                1708578000
            ],
            [
                1.24,
                1708664400
            ],
            [
                1.31,
                1708923600
            ],
            [
                1.41,
                1709010000
            ],
            [
                1.33,
                1709096400
            ],
            [
                1.16,
                1709182800
            ],
            [
                1.185,
                1709269200
            ],
            [
                1.31,
                1709528400
            ],
            [
                1.245,
                1709614800
            ],
            [
                1.33,
                1709701200
            ],
            [
                1.53,
                1709787600
            ],
            [
                1.57,
                1709874000
            ],
            [
                1.48,
                1710129600
            ],
            [
                1.45,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6569,
        "drug_name": "TAGRISSO (Osimertinib) - (ADAURA)",
        "clinical_trial_id": "NCT02511106",
        "has_trial_insight_page": 0,
        "indication": "Non-small Cell Lung Carcinoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-12-21",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20201221005157\/en\/",
        "note": "FDA approval announced December 21, 2020.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6370,
        "drug_name": "TRIKAFTA (elexacaftor\/tezacaftor\/ivacaftor and ivacaftor)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Cystic fibrosis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-12-21",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20201221005675\/en\/",
        "note": "FDA approval announced December 21, 2020.",
        "company_entity_id": 306,
        "company_ticker": "VRTX",
        "company_name": "Vertex Pharmaceuticals Incorporated",
        "company_price": "412.4500",
        "company_change": -2.02,
        "company_percent_change": -0.49,
        "company_optionable": 1,
        "company_number_of_shares": 258307816,
        "price_change_sparkline": [
            [
                433.38,
                1706677200
            ],
            [
                433.87,
                1706763600
            ],
            [
                424.68,
                1706850000
            ],
            [
                428.89,
                1707109200
            ],
            [
                416.13,
                1707195600
            ],
            [
                419.08,
                1707282000
            ],
            [
                423.06,
                1707368400
            ],
            [
                422.91,
                1707454800
            ],
            [
                418.53,
                1707714000
            ],
            [
                416.04,
                1707800400
            ],
            [
                417.88,
                1707886800
            ],
            [
                426.29,
                1707973200
            ],
            [
                422.2,
                1708059600
            ],
            [
                420.64,
                1708405200
            ],
            [
                419.63,
                1708491600
            ],
            [
                426.78,
                1708578000
            ],
            [
                430.11,
                1708664400
            ],
            [
                433.48,
                1708923600
            ],
            [
                430.92,
                1709010000
            ],
            [
                426.97,
                1709096400
            ],
            [
                420.74,
                1709182800
            ],
            [
                432.76,
                1709269200
            ],
            [
                424.03,
                1709528400
            ],
            [
                415.44,
                1709614800
            ],
            [
                411.85,
                1709701200
            ],
            [
                410.54,
                1709787600
            ],
            [
                413.59,
                1709874000
            ],
            [
                414.47,
                1710129600
            ],
            [
                412.45,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7024,
        "drug_name": "XALKORI (crizotinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "ALK-positive Anaplastic Large Cell Lymphoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-01-14",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210114006005\/en\/",
        "note": "FDA approval announced January 14, 2021.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    }
]